Journal of Hepatology
Volume 49, Issue 5 , Pages 695-701, November 2008

Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy

  • Rosendo Jardi

      Affiliations

    • Department of Biochemistry, Hospital General Universitario Vall d’Hebrón, Paseo Valle Hebrón s/n, Servicio de Bioquimica, Barcelona 08035, Spain
    • Department of Hepatology, Hospital Universitario Vall d’Hebron, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Fax: +34 93 2746831.
  • ,
  • Francisco Rodriguez-Frias

      Affiliations

    • Department of Biochemistry, Hospital General Universitario Vall d’Hebrón, Paseo Valle Hebrón s/n, Servicio de Bioquimica, Barcelona 08035, Spain
    • Department of Hepatology, Hospital Universitario Vall d’Hebron, Barcelona, Spain
  • ,
  • Melanie Schaper

      Affiliations

    • Department of Biochemistry, Hospital General Universitario Vall d’Hebrón, Paseo Valle Hebrón s/n, Servicio de Bioquimica, Barcelona 08035, Spain
    • Department of Hepatology, Hospital Universitario Vall d’Hebron, Barcelona, Spain
  • ,
  • Elena Giggi

      Affiliations

    • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
  • ,
  • David Tabernero

      Affiliations

    • Department of Hepatology, Hospital Universitario Vall d’Hebron, Barcelona, Spain
  • ,
  • Maria Homs

      Affiliations

    • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
  • ,
  • Rafael Esteban

      Affiliations

    • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
    • Department of Hepatology, Hospital Universitario Vall d’Hebron, Barcelona, Spain
  • ,
  • Maria Buti

      Affiliations

    • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
    • Department of Hepatology, Hospital Universitario Vall d’Hebron, Barcelona, Spain

Received 27 November 2007; received in revised form 13 March 2008; accepted 31 March 2008. published online 06 May 2008.

Associate Editor: F. Zoulim

Background/Aims

The frequency of mixed hepatitis B virus (HBV) genotypes in chronic HBV (CHB) and genotype changes during natural disease evolution and as a result of antiviral therapy were investigated.

Methods

Serum samples from 103 CHB patients were included in a cross-sectional study. Longitudinal study of HBV genotypes was performed in 22 patients, 17 of them under antiviral therapy (lamivudine and/or adefovir). HBV genotyping was done by the INNO-LiPA HBV assay.

Results

Genotypes observed in the cross-sectional study: A 32% of cases, D 42%, C 2%, F 2%, and mixed genotypes 22% (mainly A/D, followed by A/G). Genotype G was found in 7% of patients, always combined with other genotypes. In the longitudinal study, genotype changes were observed only in treated patients (9 cases). Genotype A strains were positively selected in 6 of them, mainly as mixed A/D. In 6 patients, selection coincided with a decrease in HBV-DNA levels.

Conclusions

A high frequency of mixed HBV genotypes was observed in our setting. Selection of genotype A strains during treatment is likely an indication that sensitivity to therapy differs between genotypes A and D. The absence of changes in untreated patients suggests that HBV genotype is stable without external factors.

Keywords: Hepatitis B virus, HBV genotypes, Genotype co-infection, Genotype switches, Chronic hepatitis B, Antiviral treatment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00244-4

doi:10.1016/j.jhep.2008.03.030

Journal of Hepatology
Volume 49, Issue 5 , Pages 695-701, November 2008